We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Automated Nasal Swab Technology Creates Hands-Free Diagnostics Workflow

By LabMedica International staff writers
Posted on 04 May 2022
Print article
Image: RHINOstic Automated Nasal swabs create hands-free diagnostics workflows (Photo courtesy of Rhinostics)
Image: RHINOstic Automated Nasal swabs create hands-free diagnostics workflows (Photo courtesy of Rhinostics)

An innovative swab technology works with a variety of automated decappers to create hands-free diagnostics workflows from the point the sample enters the lab with rapid 2D barcode accessioning through decapping and aliquoting samples into microplates containing assay master mix, removing costly labor and errors.

The RHINOstic Automated Nasal Swab from Rhinostics, Inc. (Boston, MA, USA) integrates a unique, polypropylene-based swab with an automation-friendly cap. After the nasal sample is collected, the swab is placed into a transport tube with optional 2D/1D barcodes and ready for dry transport. The hydrophobic material and lack of viral transport media (VTM) help to reduce reagent costs, leaking/aerosol risks, and viral transport media-based assay inhibitors, and aid in ensuring complete sample elution compared to antiquated foam or spun fiber swabs.

In an automated workflow with a robotic decapper and automated liquid handler, up to 96 samples may be rapidly and reproducibly accessioned, decapped, and processed into assay plates at once versus the manual process, which can take up to 18 minutes to process the same number of samples. This enables high throughput workflows with minimal manual intervention, supports robust data, and instant scalability to meet surging sample demands without increasing labor costs. It also allows laboratories to manage their staff, where COVID-19 surges will not require armies of temporary workers but instead, relies on robotics to manage the increase of samples during peak times while lowering per sample labor costs to roughly USD 0.50 per sample.

Related Links:
Rhinostics, Inc.

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Negative Third-Party QC for IgM Antibodies to SARS-C0V-2
Multichem ID-COVID19Neg
New
Silver Supplier
Modular Sequencing Workstation
MGIFLP-L200
New
ELISA & CLIA Analyzer
Autoplex Gen2

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.